SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : ADOT - BIOMODA: Profitable Technology with Purpose
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Major Tom who wrote (1633)9/11/1998 1:49:00 PM
From: Brad   of 4650
 
Major Tom, The Auditor's report estimated Biomoda's share value at $1.50 per share as of last March 31, 1998. That was BEFORE the LungCheck results.

Biomoda said they might do one small private placement of 100 to 200 thousand shares to cover some development costs related to Consumer Kit production. The price would be at about $1.50 to $2.00 per share.

They said they have enough cash to handle it, but a small private placement like this would just provide a little extra breathing room. That private placement will have to happen VERY soon because once the LungCheck results are in, the whole complexion changes and Biomoda's selling price goes up.

Then... the next stage (after the LungCheck results)...

If Biomoda is not sold and they continue their own development process, they would then do a larger private placement at around $3.50 to $4.00 and do about 1 million shares. That would take them to the next level in their THERAPEUTIC development. THERAPEUTICS requires FDA approval, DIAGNOSTICS does NOT!

Then they would be ready for an IPO at probably the $10 to $20 level and they would do that with another 1 million shares.

The "wild card" in all of this is the possibility of a buyout. ScheringAG/Berlex is probably most interested in the DIAGNOSTICS if you look at the type of thing they do. So Biomoda could sell the DIAGNOSTICS to one buyer and the THERAPEUTICS to another. Or they could sell just one part and develop the other on their own.

I could be wrong, but that's how I see it.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News